Lv1
80 积分 2021-07-19 加入
Letter: Transition of Hematological Indexes in 36-Week Treatment with Lebrikizumab for Atopic Dermatitis: A Real-World Prospective Japanese Study
2个月前
已完结
Letter: Long-Term Safety and Effectiveness of Lebrikizumab Treatment for Moderate-to-Severe Atopic Dermatitis Stratified by Age Groups in Real-World Clinical Practice in Japan
2个月前
已完结
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study
2个月前
已完结
Ocular toxicity associated with mirvetuximab soravtansine: navigating clinical relevance and divergent regulatory recommendations
2个月前
已完结
620P Efficacy and safety of mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer beyond third-line therapy: A retrospective real-world Chinese study
2个月前
已完结
Ocular toxicity associated with mirvetuximab soravtansine: navigating clinical relevance and divergent regulatory recommendations
2个月前
已完结
Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy
2个月前
已完结
Efficacy, safety, and quality of life in patients aged ≥75 years in MIRASOL (GOG 3045/ENGOT-ov55): mirvetuximab soravtansine vs investigator’s choice chemotherapy in folate receptor alpha-positive platinum-resistant ovarian cancer
2个月前
已完结
皖公网安备34019202002308
